论文部分内容阅读
目的 观察尼妥珠单抗联合放化疗治疗局部晚期头颈部恶性肿瘤的临床疗效.方法 随机将医院科室治疗的局部晚期头颈部肿瘤患者78例分为观察组和对照组, 每组39例.对照组单用根治性同步放化疗, 在此基础上观察组使用尼妥珠单抗治疗, 比较2组患者的近期疗效、1年生存率、不良反应.结果 观察组临床控制率为66. 67％、治疗有效率为94. 87％, 高于对照组的43. 59％、76. 92％(P均<0.05);观察组1年生存率为89. 74％, 明显高于对照组的53. 85％(P 0.05).结论 尼妥珠单抗联合放化疗治疗局部晚期头颈部恶性肿瘤的临床效果显著, 可延长患者生存时间, 药物不良反应轻微, 具有积极的临床意义.“,”Objective To observe the clinical effect of Nimotuzumab combined with radiotherapy and chemotherapy in the treatment of locally advanced head and neck malignant tumors. Methods Seventy-eight patients with locally advanced head and neck tumors were randomly divided into observation group and control group, 39 cases in each group. The control group was treated with radical concurrent radiotherapy and chemotherapy alone, while the observation group was treated with Nimotuzumab on the basis of the control group. The short-term efficacy, 1-year survival rate and adverse reactions of the two groups were compared. Results The clinical control rate and the effective rate of treatment in the observation group were66. 67％ and 94. 87％ respectively, which were higher than those in the control group (43. 59％ and 76. 92％, P < 0. 05).The 1-year survival rate of the observation group was 89. 74％, which was higher than 53. 85％ of the control group (P 0. 05). Conclusion Nimotuzumab combined with radiotherapy and chemotherapy in the treatment of locally advanced head and neck malignant tumors has a significant clinical effect. It can prolong the survival time of patients with mild adverse drug reactions and has a positive clinical significance.